Divi's Laboratories Ltd.
NSE: DIVISLAB · Pharmaceuticals
Snapshot
Unlock Divi's Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Divi's Laboratories Limited is a prominent manufacturer of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. The company also provides custom synthesis services for global pharmaceutical firms and supplies a diverse range of carotenoids and vitamins.
Business Model
The company generates revenue through the large-scale manufacturing of APIs and intermediates, alongside a robust custom synthesis business for multinational pharmaceutical partners. It further diversifies its income by supplying nutritional ingredients to the food, beverage, and feed industries.
Growth Outlook
Growth is primarily driven by the expansion of custom synthesis projects and the increasing global demand for high-quality generic APIs. The company continues to leverage its manufacturing capabilities to capture opportunities in the nutraceutical and vitamin markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by global health authorities like the US FDA.
- Currency Volatility. As a major exporter, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins.
- Supply Chain Dependencies. Reliance on imported raw materials and intermediates makes the company vulnerable to global supply chain disruptions and price volatility.
- Pricing Pressure. Intense competition in the generic API market may lead to pricing pressures and margin compression.
Start your research today
Unlock AI insights, financials, peers and live data on Divi's Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹11,230 Cr
TTM · consolidated
NET PROFIT
₹2,925 Cr
TTM · consolidated
EPS
₹110.21
TTM · consolidated
RETURN ON EQUITY
18.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.1%
TTM · consolidated
P/E
82.6x
Q1 FY27 · consolidated
EV/EBITDA
54.6x
Q1 FY27 · consolidated
EBITDA MARGIN
39.3%
TTM · consolidated
NET PROFIT MARGIN
29.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Divi's Laboratories Ltd.DIVISLAB | ₹2.42L Cr | 82.57 | 54.64 | 16.3% | 39.3% | 18.4% | 23.1% | +48.4% |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.85L Cr | 77.59 | 38.74 | 32.9% | 32.6% | 27.0% | 15.1% | +34.9% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.13L Cr | 24.96 | 14.08 | 21.1% | 30.7% | 18.0% | 20.1% | +10.7% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
Laurus Labs Ltd.LAURUSLABS | ₹99,334 Cr | 90.82 | 48.68 | 22.6% | 28.7% | 22.3% | 25.3% | +110.5% |
Lupin Ltd.LUPIN | ₹96,476 Cr | 17.44 | 9.81 | 28.2% | 33.4% | 28.0% | 34.5% | +8.8% |
As of Q1 FY27
Financials
Divi's Laboratories Ltd.
NSE: DIVISLAB · Pharmaceuticals
Snapshot
Unlock Divi's Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Divi's Laboratories Limited is a prominent manufacturer of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients. The company also provides custom synthesis services for global pharmaceutical firms and supplies a diverse range of carotenoids and vitamins.
Business Model
The company generates revenue through the large-scale manufacturing of APIs and intermediates, alongside a robust custom synthesis business for multinational pharmaceutical partners. It further diversifies its income by supplying nutritional ingredients to the food, beverage, and feed industries.
Growth Outlook
Growth is primarily driven by the expansion of custom synthesis projects and the increasing global demand for high-quality generic APIs. The company continues to leverage its manufacturing capabilities to capture opportunities in the nutraceutical and vitamin markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent inspections and quality standards imposed by global health authorities like the US FDA.
- Currency Volatility. As a major exporter, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins.
- Supply Chain Dependencies. Reliance on imported raw materials and intermediates makes the company vulnerable to global supply chain disruptions and price volatility.
- Pricing Pressure. Intense competition in the generic API market may lead to pricing pressures and margin compression.
Start your research today
Unlock AI insights, financials, peers and live data on Divi's Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹11,230 Cr
TTM · consolidated
NET PROFIT
₹2,925 Cr
TTM · consolidated
EPS
₹110.21
TTM · consolidated
RETURN ON EQUITY
18.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.1%
TTM · consolidated
P/E
82.6x
Q1 FY27 · consolidated
EV/EBITDA
54.6x
Q1 FY27 · consolidated
EBITDA MARGIN
39.3%
TTM · consolidated
NET PROFIT MARGIN
29.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27